Genomic Testing that Facilitates the Identification and Treatment of Cancer

FDA-APPROVED ASSAY

Efficient, and  Actionable Outcomes.



Oncology Comprehensive Solutions


Cancer remains one of the most significant global health challenges, requiring precision medicine approaches to improve treatment outcomes. SolidTumorCheck+, powered by Next-Generation Sequencing (NGS), provides a comprehensive genomic profiling (CGP) solution to identify actionable mutations, enabling oncologists to tailor treatments for cancer patients based on their unique tumor genetics. This FDA-approved assay (IVD) serves as a companion diagnostic (CDx) to guide the selection of targeted therapies and immunotherapies for patients with solid tumors, in alignment with regulatory-approved drug indications and professional oncology guidelines.

Why Choose SolidTumorCheck+ Comprehensive?

✅ FDA-approved & clinically validated
✅ Covers 517 DNA & 24 RNA fusion genes
✅ Identifies key biomarkers for targeted therapies & immunotherapy
✅ Provides critical TMB scoring for immunotherapy response assessment
✅ Fast turnaround (10 days) for rapid clinical decision-making

For oncologists, molecular pathologists, clinical researchers and Cancer institutes, SolidTumorCheck+ is an essential tool for delivering precision cancer care in today’s evolving oncology landscape.


Oncology Comprehensive -
SolidTumorCheck+

FDA-Approved Assay  

It sequences over 517 genes known to be relevant to cancer treatment and assesses essential immunotherapy (IO) biomarkers, providing oncologists with a comprehensive view to devise tailored treatment plans for their patients. Genomic Testing that Facilitates the Identification and Treatment of Cancer.

services image

Product Features

Gene Analysis Assay

500+ solid tumor related genes with broad coverage of key guidelines and clinical trials for multiple solid tumor types.

Turnaround Time

You can expect results in approximately three weeks, facilitated by either manual or automated workflows that encompass library preparation, sequencing, and data analysis.

Accurate

Sensitivity of 98.91% Specificity >99.99% using Orthogonal methods, Including DNA and RNA. Accurately measures TMB, MSI, SNVs, INDELs, CNVs, structural variations, and gene fusions.

Enabling Flexible, Scalable Comprehensive Genomic Profiling from FFPE samples

Comprehensive Pan-Cancer Panel High-Throughput includes key guideline biomarkers for multiple cancer types, plus pan-cancer biomarkers such as MSI, NTRK1-3, and TMB.

some key Cancer-specific biomarkers include:

Lung

AKT1, ALK, BRAF, DDR2, EGFR, ERBB2, FGFR1, FGFR3, KRAS, MAP2K1, MET, NRAS, PIK3CA, PTEN, RET, TP53

Melanoma

BRAF, CTNNB1, GNA11, GNAQ, KIT, MAP2K1, NF1, NRAS, PDGFRA, PIK3CA, PTEN, TP53

Colon

AKT1, BRAF, HRAS, KRAS, MET, MLH1, MSH2, MSH6, NRAS, PIK3CA, PMS2, PTEN, SMAD4, TP53

Ovarian

BRAF, BRCA1, BRCA2, KRAS, PDGFRA, FOXL2, TP53

Breast

AKT1, AR, BRCA1, BRCA2, ERBB2, FGFR1, FGFR2, PIK3CA, PTEN

Gastric

BRAF, KIT, KRAS, MET,MLH1, PDGFRA, TP53

Bladder

MSH6, PMS2, TSC1

Sarcoma

ALK, APC, BRAF, CDK4, CTNNB1, ETV6, EWSR1, FOXO1, GLI1, KIT, MDM2, MYOD1, NAB2, NF1, PAX3, PAX7, PDGFRA, PDGFRB, SDHB, SDHC, SMARCB1, TFE3, WT1

Provide Clinical Results with Confidence

Advanced interpretation technology to deliver timely and more accurate variant identification.

Relevant treatment options and the most precise clinical results, all in a physician-ready report. This technology is backed by a comprehensive knowledge-base and a powerful rules engine that takes many disparate inputs from our knowledge- base and distills them into concise interpretations and connections supporting evidence.

With over 350,000 rules in place, characteristics of patient variants are leveraged to surface the most optimal treatment possibilities.

iPhone - Elements Webflow Library - BRIX Templates

Determine by Identify

PreCheck offers a range of genetic tests designed for various conditions. Each test comes with clear follow-up recommendations, enabling healthcare providers to make personalized decisions based on your genetic profile.